Details
Industries BiotechnologyLife ScienceTherapeuticsHeadquarters Regions Greater New York Area, East Coast, Northeastern US Founded Date 2018 Founders Ronald G. Crystal Operating Status Active Last Funding Type Post-IPO Equity Legal Name Lexeo Therapeutics, Inc.
Stock Symbol NASDAQ:LXEO Company Type For Profit
Contact Email info@lexeotx.com Phone Number (212) 547-9879
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single gene
mutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.
Products and Services
Product Name | Product Description |
---|---|